Pathophysiology of Thrombotic Thrombocytopenic Purpura
TTP results from severe deficiency of the plasma protease ADAMTS13 (activity <10%), which normally cleaves ultra-large von Willebrand factor (UL-VWF), leading to uncontrolled accumulation of UL-VWF that triggers excessive platelet adhesion, aggregation, and widespread microvascular thrombosis causing ischemic organ damage and potentially death 1.
The Central Mechanism: ADAMTS13 Deficiency
The pathophysiology centers on a critical enzymatic failure. ADAMTS13 is produced primarily in hepatic stellate cells and endothelial cells, then released into the bloodstream where it performs essential proteolytic cleavage of UL-VWF 1. This cleavage is crucial for:
- Normal hemostasis regulation
- Control of inflammatory responses
- Prevention of spontaneous platelet aggregation
When ADAMTS13 activity falls below 10% of normal, the system fails catastrophically 1, 2.
Two Distinct Etiologies
Immune TTP (iTTP) - Most Common in Adults
Autoantibodies against ADAMTS13 cause acquired deficiency, accounting for the majority of adult cases 1. The autoantibodies either:
- Inhibit ADAMTS13 enzymatic activity directly
- Accelerate clearance of ADAMTS13 from circulation
- Form immune complexes that are rapidly removed
Critical caveat: Absence of detectable anti-ADAMTS13 antibodies during acute episodes does NOT rule out iTTP, as free antibodies may be undetectable by ELISA due to immune complex formation or accelerated clearance 1.
Congenital TTP (cTTP) - Hereditary Form
Biallelic mutations in the ADAMTS13 gene (approximately 250 mutations identified) cause hereditary deficiency 1. These mutations result in:
- Impaired secretion of ADAMTS13 protein into bloodstream
- Production of non-functional ADAMTS13 protease
- Most patients carry compound heterozygous mutations, though homozygous mutations occur
The Thrombotic Cascade
When ADAMTS13 is severely deficient, UL-VWF accumulates at three critical sites 1:
- On endothelial surfaces
- At sites of vascular injury
- In circulating blood
This accumulated UL-VWF remains in its elongated, hyperactive form and triggers:
- Excessive platelet adhesion via interaction with platelet glycoprotein Ib
- Platelet aggregation in arterioles and capillaries
- Microvascular thrombus formation throughout the body (the pathognomonic feature)
Clinical Consequences
The widespread microvascular thrombosis produces the characteristic pentad (though not all features are always present):
Hematologic manifestations:
- Severe thrombocytopenia (usually <30 × 10⁹/L) from platelet consumption
- Microangiopathic hemolytic anemia from red blood cell fragmentation (schistocytes) as erythrocytes shatter passing through microthrombi 3
- Elevated lactate dehydrogenase
- Low hemoglobin and haptoglobin
- Negative direct antiglobulin test (DAT-negative hemolysis)
Organ ischemia from microvascular occlusion:
- Central nervous system (most common) - neurologic deficits, altered mental status
- Cardiac involvement
- Renal dysfunction
- Variable degrees of end-organ damage 1
Important Pathophysiologic Nuances
ADAMTS13 deficiency alone may be insufficient to trigger acute TTP 2. Evidence suggests additional factors are required:
- Environmental triggers (infection, pregnancy, drugs)
- Additional genetic predisposition
- This explains why some patients with chronic ADAMTS13 deficiency remain asymptomatic until a precipitating event occurs
The disease is chronic with episodic acute manifestations - patients have persistent ADAMTS13 deficiency but experience intermittent acute thrombotic episodes 2.
Diagnostic Implications
The pathophysiology directly informs diagnosis: ADAMTS13 activity <10 IU/dL (or 10% of normal) in the proper clinical context confirms TTP 1. However, treatment must begin before results are available given the rapid progression and high mortality without intervention 2.
This understanding has revolutionized TTP from a nearly universally fatal disease to one with >95% survival when promptly recognized and treated 2.